Dermapharm Holding SE (FRA:DMP) ROCE %: 15.50% (As of Mar. 2026)


FRA:DMP Dermapharm Holding SE FRA:DMP
87 GF Score
Price €46.25
GF Value €39.11
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Dermapharm Holding SE ROCE %?

Dermapharm Holding SE FRA:DMP -0.64% 87 ROCE % is 15.50% as of Mar. 2026. GuruFocus rates FRA:DMP with a GF Score™ of 87/100 and a GF Value™ of €39.11 (Modestly Overvalued). The stock has 9 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Dermapharm Holding SE's annualized ROCE % for the quarter that ended in Mar. 2026 was 15.50%.

Dermapharm Holding SE  (FRA:DMP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Dermapharm Holding SE ROCE % Related Terms

Dermapharm Holding SE ROCE % Historical Data

* Premium members only.

The historical data trend for Dermapharm Holding SE's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dermapharm Holding SE ROCE % Chart

Dermapharm Holding SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.76 18.69 10.87 13.09 12.91

Dermapharm Holding SE Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.06 10.21 15.97 11.80 15.50
FRA:DMP
87GF Score
Dermapharm Holding SE FRA:DMP
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dermapharm Holding SE ROCE % Calculation

Dermapharm Holding SE's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=232.183/( ( (2080.019 - 326.915) + (2186.8 - 342.93) )/ 2 )
=232.183/( (1753.104+1843.87)/ 2 )
=232.183/1798.487
=12.91 %

Dermapharm Holding SE's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=288.756/( ( (2186.8 - 342.93) + (2272.666 - 390.241) )/ 2 )
=288.756/( ( 1843.87 + 1882.425 )/ 2 )
=288.756/1863.1475
=15.50 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 15.50% mean?
Dermapharm Holding SE (FRA:DMP) has a ROCE % of 15.50% as of Mar. 2026.
Is Dermapharm Holding SE's ROCE % too high?
Dermapharm Holding SE's current ROCE % is 15.50%. The Drug Manufacturers industry median ROCE % is 7.00. Dermapharm Holding SE's value of 15.50% is 121.6% above this industry median. Overall, Dermapharm Holding SE has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's ROCE % compare to ZTS and UTHR?
Dermapharm Holding SE's ROCE % of 15.50% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Dermapharm Holding SE's value of 15.50% is 121.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dermapharm Holding SE's current ROCE % of 15.50% is 121.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current ROCE % is 15.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Based on GuruFocus' analysis, Dermapharm Holding SE (FRA:DMP) is currently considered Modestly Overvalued. The stock's GF Value™ is €39.11, compared to a current price of €46.25 — trading 18.3% above its estimated fair value. The current ROCE % is 15.50% and 121.6% above the Drug Manufacturers industry median of 7.00. Dermapharm Holding SE's overall GF Score™ is 87/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Dermapharm Holding SE (FRA:DMP), the current ROCE % is 15.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dermapharm Holding SE (FRA:DMP) Overvalued in 2026?

Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be overvalued. The current stock price of €46.25 is trading 18.3% above its estimated GF Value™ of €39.11. GuruFocus considers Dermapharm Holding SE to be Modestly Overvalued.

Key valuation signals for FRA:DMP:

  • ROCE %: 15.50%
  • GF Value™: €39.11 vs. price of €46.25 (18.3% above fair value)
  • GF Score™: 87/100 with 9 warning signs
  • Industry Position: 121.6% above the Drug Manufacturers median

No single metric tells the full story. See the FRA:DMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dermapharm Holding SE Business Description

Address Lil-Dagover-Ring 7, Grunwald, BY, DEU, 82031
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
87GF Score

Get the complete analysis for FRA:DMP

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.25
Price
€39.11
GF Value